Live Breaking News & Updates on Long Term Weight

Stay updated with breaking news from Long term weight. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Best Meal Replacement Shakes that Really Work for Weight Loss

Looking for the best meal replacement shakes for weight loss? Here are some of the best meal replacement shakes on the market. ....

United Kingdom , National Health Service , Group Swimmers , Biomed Research International , Best Meal Replacement Shakes , Really Work , Knockout Complete , Meal Replacement Shake , Nutritional Shake , Labs Meal Replacement Powders , Fat Burning Meal Replacement , Plant Protein , Whole Body Meal , Lean Meal Shake , None Organic , Vegan Meal Replacement , Diet Meal Shakes , Meal Replacement Shakes , Instant Knockout , Soy Protein , Golden Flaxseed , Instant Knockout Complete , Fullest Everyday , Brown Rice Protein , Sugar Beet , Tapioca Prebiotic ,

10 Weight Loss Myths

With so much information available on the topic, it can be hard to separate facts from weight loss myths. ....

Can Spot Reduce , Crash Diets Are Effective , Long Term Weight , Carbs Are Bad , Low Fat Foods Are Always , Skipping Meals Will , Only Way , Weight Loss Supplements Are , Eating Late , Night Causes Weight , All Calories Are , Slow Metabolism ,

Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society

Alkermes Presents New Data From Psychiatry Portfolio at Virtual 2021 Congress of the Schizophrenia International Research Society
- New Exploratory Analyses Presented From ENLIGHTEN-2 Study of LYBALVI™ in Patients With Schizophrenia -
News provided by
Share this article
Share this article
DUBLIN, April 20, 2021 /PRNewswire/ Alkermes plc (Nasdaq: ALKS) today announced the presentation of new research from its psychiatry portfolio at the 2021 Congress of the Schizophrenia International Research Society (SIRS), taking place virtually April 17-21, 2021.
The company s presentations included new exploratory analyses from the phase 3 ENLIGHTEN-2 study of olanzapine/samidorphan (LYBALVI™), formerly referred to as ALKS 3831, including:
Results from prespecified subgroup analyses evaluating olanzapine/samidorphan s effect on weight gain across several patient subgroups, including those known to be at higher risk for weight gain with olanzapine, based ....

United States , Craig Hopkinson , Marisa Borgasano , Aripiprazole Lauroxil , Sandy Coombs , Exchange Commission , Schizophrenia International Research Society , Alkermes Pharma Ireland , Research Development , Executive Vice President , Chief Medical Officer , Patients Known , Increased Risk , Weight Gain With Olanzapine Treatment , With Olanzapine , Results From , Week Phase , Long Term Safety , Samidorphan Combination , Patients With Schizophrenia , Pooled Analyses From Phase , Long Term Weight , Metabolic Effects , Long Term Antipsychotic Efficacy , Vivo Characterization , Opioid Receptor Binding Profiles ,